Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding-Reference-Cited by-同舟云学术

Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding

Published:2021-11-01 Issue:3 Volume:88 Page:234-237
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:

Author:

Ciccullo Arturo,Borghi Vanni,Giacomelli Andrea,Cossu Maria Vittoria,Sterrantino Gaetana,Latini Alessandra,Giacometti Andrea,De Vito Andrea,Gennari William,Madeddu Giordano,Capetti Amedeo,d’Ettorre Gabriella,Mussini Cristina,Rusconi Stefano,Di Giambenedetto Simona,Baldin Gianmaria

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference12 articles.

1. Current and emerging two-drug approaches for HIV-1 therapy in ART-naïve and ART-experienced, virologically suppressed patients;Rossetti;Expert Opin Pharmacother.,2018

2. Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial;Fabbiani;J Antimicrob Chemother.,2018

3. Dual therapy with darunavir and ritonavir plus lamivudine vs triple therapy with darunavir and ritonavir plus tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine for maintenance of human immunodeficiency virus type 1 viral Suppression: randomized, open-label, noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial;Pulido;Clin Infect Dis.,2017

4. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial;Arribas;Lancet Infect Dis,2015

5. Lamivudine plus darunavir boosted with ritonavir as simplification dual regimen in HIV-infected patients;Casado;J Int AIDS Soc.,2014

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current status of the small molecule anti-HIV drugs in the pipeline or recently approved;Bioorganic & Medicinal Chemistry;2024-09

2. Incorporating temporal dynamics of mutations to enhance the prediction capability of antiretroviral therapy’s outcome for HIV-1;Bioinformatics;2024-05-22

3. Efficacy of Lamivudine Plus Dolutegravir vs Dolutegravir-Based 3-Drug Regimens in People With HIV Who Are Virologically Suppressed;Open Forum Infectious Diseases;2024-04-10

4. Switching to Dolutegravir/Lamivudine Two-Drug Regimen: Durability and Virologic Outcomes by Age, Sex, and Race in Routine US Clinical Care;HIV/AIDS - Research and Palliative Care;2024-04

5. Dolutegravir/Lamivudine Is Noninferior to Continuing Dolutegravir- and Non-Dolutegravir-Based Triple-Drug Antiretroviral Therapy in Virologically Suppressed People With Human Immunodeficiency Virus: DUALING Prospective Nationwide Matched Cohort Study;Open Forum Infectious Diseases;2024-03-18